Completed PHASE2 INTERVENTIONAL NCT00205647

Study of Expectorant Activity of Oral N-acetylcystein (NAC) in Patients With Stable Chronic Bronchitis

A Phase II Multicenter Efficacy, Safety and Dose-Effect Study of the Expectorant Activity of Oral N-acetylcystein (NAC) in Patients With Stable, Chronic Bronchitis

Sponsor: Wake Forest University

Conditions Chronic Bronchitis

Interventions Oral N-acetycystein (NAC)

Updated 7 times since 2017 Last updated: Nov 1, 2017 Started: Jan 31, 1997 Completion: Mar 31, 2000

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Chronic Bronchitis and is currently completed. Wake Forest University leads this study, which shows 7 recorded versions since 1997 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Dec 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Dec 2017 [monthly]

Completed PHASE2

First recorded

Jan 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Wake Forest University
Zambon SpA

Data source: Wake Forest University Health Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Winston-Salem, United States